Molecular Partners AG Announces Publication of Results From a Phase I/II Clinical Trial of Its anti-VEGF DARPin MP0112 in Diabetic Macular Edema
1/17/2013 9:52:15 AM
More...
|
Allergan Inc. (AGN), Molecular Partners AG Ink $1.5 Billion Exclusive Pact
8/21/2012 6:46:43 AM
More...
|
Molecular Partners AG Strengthens Management Team With the Appointment of Lisa Rojkjaer, MD as Chief Medical Officer
5/31/2012 10:13:52 AM
More...
|
Molecular Partners AG Comments on Allergan Inc. (AGN)'s Progress in Phase IIa Retinal Disease Trial Using Anti-VEGF DARPin®
4/5/2012 9:14:07 AM
More...
|
Johnson & Johnson (JNJ)'s Janssen Biotech Inc. and Molecular Partners AG Expand Agreement to Immunological Diseases in Deal Worth $800 Million
12/8/2011 6:55:49 AM
More...
|
Swiss Biotech IPOs Including Molecular Partners AG May Revive Health-Care Industry Starved of Investment
7/8/2011 8:28:22 AM
More...
|
Allergan Inc. (AGN) and Molecular Partners AG Enter Exclusive License Agreement for MP0112; Molecular Partners to Receive $45 Million Upfront and up to $375 Million in Milestone Payments
5/4/2011 8:24:47 AM
More...
|
Molecular Partners AG Reports Positive Results from Its First Clinical Studies
4/28/2011 10:29:06 AM
More...
|
Molecular Partners AG Reports Positive Results from its First Clinical Studies
4/28/2011 8:54:08 AM
More...
|
Molecular Partners AG Progresses Darpin Into First-In-Humans Clinical Studies
4/30/2010 1:41:07 PM
More...
|
|